Delivering Twice As Many Pharmaceuticals At Half The Cost Is Now A Reality
Wednesday, December 3, 2014
Eulysis UK Limited’s mission is to revolutionise pharmaceutical delivery globally. The Single Vial System (SVS), their unique storage and reconstitution technology for lyophilized (freeze-dried) pharmaceuticals is just 9 months away from becoming commercially viable.
With the development of the Single Vial System (SVS), Eulysis UK Limited has positioned itself at the forefront of developing innovative pharmaceutical delivery methods. Consolidating the two separate primary containers into a single integrated and compartmentalised SVS is made possible through an advanced manufacturing process that allows the integration of lyophilized (freeze-dried) active ingredients and the appropriate diluent to allow reconstitution in the same container. Founder, Ross Tsakashas been able to raise $3.2 million to commercialize this patented pharmaceutical delivery technology over the next 9 months, which would make drug production significantly cheaper.
SVS has numerous uses including, but not limited to vaccines, antibiotics, antidotes, oncology and defence medicines. Its competitive advantages are enhanced product safety, reduced risk of contamination, cost efficient production and supply chain, minimizing environmental impact and doubly expanding the access to pharmaceuticals and life-saving medicines globally. Crucially, the technology cuts pharmaceutical packaging costs by up to 50%, allowing expanded access at a discounted rate.
Eulysis won one of the four $500K awards as a runner-up in 43North, the world’s largest business idea competition that received 6,932 applications from 96 countries and all 50 states in its inaugural year. The company also raised an additional $100K from the Google Cloud Platform and have just secured follow-on investment of $1.5 million.
- Health Care